Drug intelligence / Profile preview

human umbilical cord stroma-derived multipotent stromal cells

Development stage: Phase 1
Lead developer: Ankara University
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intramyocardial

Overview

This investigational cell therapy consists of allogeneic human umbilical cord stroma-derived multipotent stromal cells (hUCS-MSCs) harvested from Wharton's jelly. Developed by Ankara University, the therapy is intended for the treatment of chronic ischemic cardiomyopathy. The cells are produced under current Good Manufacturing Practice (cGMP) conditions and are administered via intramyocardial delivery into peri-infarcted myocardium, typically in conjunction with coronary artery bypass grafting (CABG) surgery. The mechanism of action involves pro-angiogenic and anti-inflammatory properties that promote cardiac regeneration and reduce the formation of scar tissue. Clinical results from the Phase 1/2 HUC-HEART trial indicated improvements in left ventricular ejection fraction and a reduction in necrotic myocardial volume compared to control groups.

Other names: allogeneic human umbilical cord-derived mesenchymal stromal cellsWharton's jelly-derived mesenchymal stem cellshUCS-MSC

Beyond the preview

Go deeper on human umbilical cord stroma-derived multipotent stromal cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human umbilical cord stroma-derived multipotent stromal cells.

Explore the full profile